» Articles » PMID: 33041859

Increased Transglutaminase 2 Expression and Activity in Rodent Models of Obesity/Metabolic Syndrome and Aging

Overview
Journal Front Physiol
Date 2020 Oct 12
PMID 33041859
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Diastolic dysfunction of the heart and decreased compliance of the vasculature and lungs (i.e., increased organ tissue stiffness) are known features of obesity and the metabolic syndrome. Similarly, cardiac diastolic dysfunction is associated with aging. Elevation of the enzyme transglutaminase 2 (TG2) leads to protein cross-linking and enhanced collagen synthesis and participates as a candidate pathway for development of tissue stiffness. With these observations in mind we hypothesized that TG2 may be elevated in tissues of a rat model of obesity/metabolic syndrome (the ZSF 1 rat) and a mouse model of aging, i.e., the senescent SAMP8 mouse. In the experiments reported here, TG2 expression and activity were found for the first time to be spontaneously elevated in organs from both the ZSF1 rat and the SAMP8 mouse. These observations are consistent with a hypothesis that a TG2-related pathway may participate in the known tissue stiffness associated with cardiac diastolic dysfunction in these two rodent models. The potential TG2 pathway needs better correlation with physiologic dysfunction and may eventually provide novel therapeutic insights to improve tissue compliance.

Citing Articles

Simultaneous Positron Emission Tomography and Molecular Magnetic Resonance Imaging of Cardiopulmonary Fibrosis in a Mouse Model of Left Ventricular Dysfunction.

Moon B, Zhou I, Ning Y, Chen Y, Le Fur M, Shuvaev S J Am Heart Assoc. 2024; 13(14):e034363.

PMID: 38979786 PMC: 11292745. DOI: 10.1161/JAHA.124.034363.


Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery.

Gao S, Liu X, Li T, Chen L, Feng Y, Wang Y Acta Pharmacol Sin. 2023; 45(1):23-35.

PMID: 37644131 PMC: 10770177. DOI: 10.1038/s41401-023-01152-0.


Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.

Withaar C, Lam C, Schiattarella G, de Boer R, Meems L Eur Heart J. 2021; 42(43):4420-4430.

PMID: 34414416 PMC: 8599003. DOI: 10.1093/eurheartj/ehab389.


The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment.

Tempest R, Guarnerio S, Maani R, Cooper J, Peake N Cancers (Basel). 2021; 13(11).

PMID: 34205140 PMC: 8199963. DOI: 10.3390/cancers13112788.


Transglutaminases Are Active in Perivascular Adipose Tissue.

Orr A, Thompson J, Lyttle J, Watts S Int J Mol Sci. 2021; 22(5).

PMID: 33808023 PMC: 7961980. DOI: 10.3390/ijms22052649.

References
1.
Bhedi C, Nasirova S, Toksoz D, Warburton R, Morine K, Kapur N . Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling. FASEB J. 2020; 34(1):930-944. PMC: 6956703. DOI: 10.1096/fj.201902155R. View

2.
Steppan J, Sikka G, Jandu S, Barodka V, Halushka M, Flavahan N . Exercise, vascular stiffness, and tissue transglutaminase. J Am Heart Assoc. 2014; 3(2):e000599. PMC: 4187484. DOI: 10.1161/JAHA.113.000599. View

3.
Greenberg C, Birckbichler P, Rice R . Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991; 5(15):3071-7. DOI: 10.1096/fasebj.5.15.1683845. View

4.
Biernacka A, Frangogiannis N . Aging and Cardiac Fibrosis. Aging Dis. 2011; 2(2):158-173. PMC: 3153299. View

5.
Asbun J, Villarreal F . The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006; 47(4):693-700. DOI: 10.1016/j.jacc.2005.09.050. View